← Back to Search

Cognitive Training for Depression

N/A
Waitlist Available
Led By Rebecca B Price, PhD
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
1. be between the ages of 18 and 80 years
2. score ≥20 on the Montgomery-Asberg Depression Rating Scale (MADRS)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months post-induction
Awards & highlights

Summary

In a sample of patients already receiving ketamine treatment as part of their clinical care, this project seeks to test whether we can enhance and/or extend ketamine's rapid effects by introducing helpful information delivered by a computer-based cognitive training protocol. This work could ultimately lead to the ability to treat depression more efficiently and with broader dissemination by rapidly priming the brain for helpful forms of learning.

Who is the study for?
This trial is for individuals already receiving ketamine treatment for depression. It aims to see if adding a computer-based cognitive training can improve the effects of ketamine.
What is being tested?
The study is testing whether a special computer program called 'Cognitive Training' can make ketamine treatment more effective for depression, compared to a fake version of the program known as 'Sham Training'.
What are the potential side effects?
Since this trial focuses on cognitive training, side effects may be minimal and related to using computers or software. However, any ongoing side effects from ketamine treatments will still apply.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months post-induction
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months post-induction for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Montgomery Asberg Depression Rating Scale: After Ketamine Induction
Montgomery Asberg Depression Rating Scale: During Ketamine Induction
Secondary study objectives
Beck Hopelessness Scale
Cognitive Triad Inventory
Montgomery Asberg Depression Rating Scale: Naturalistic Follow-up
+7 more
Other study objectives
Acceptability, Appropriateness, and Feasibility
Awe Experience Scale (AWE-S)
Client Satisfaction Questionnaire (CSQ-8)
+14 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Cognitive TrainingExperimental Treatment1 Intervention
Web-based cognitive training
Group II: Sham TrainingPlacebo Group1 Intervention
Web-based sham training
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cognitive Training
2008
Completed Phase 3
~4100

Find a Location

Who is running the clinical trial?

University of PittsburghLead Sponsor
1,741 Previous Clinical Trials
16,339,417 Total Patients Enrolled
120 Trials studying Depression
34,076 Patients Enrolled for Depression
National Institute of Mental Health (NIMH)NIH
2,840 Previous Clinical Trials
2,712,372 Total Patients Enrolled
679 Trials studying Depression
257,269 Patients Enrolled for Depression
Rebecca B Price, PhDPrincipal InvestigatorUniversity of Pittsburgh
3 Previous Clinical Trials
550 Total Patients Enrolled
1 Trials studying Depression
150 Patients Enrolled for Depression
~400 spots leftby Jun 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top